UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC

Inclusion Criteria: * Participant must have histological or cytological proven diagnosis of advanced (stage IV) NSCLC without known EGFR-sensitizing mutation or ALK/ROS1 rearrangements and/or histological or cytological proven diagnosis of advanced or metastatic MPM (according to the 8th Edition of the UICC TNM Classification). * Participant must have experienced disease progression or recurrence during or after at least one systemic therapy for advanced metastatic disease: * Participant must be able to provide adequate archival tumor tissue specimen for central somatic (s)HRd and PD-L1 status assessment, which may have been collected at any time prior to screening. If no archival FFPE tumor tissue is available, a newly obtained tissue biopsy is required before Cycle 1/Day 1. * Participant must be able to provide adequate pre-treatment blood samples for central germline (g)HRd assessment. * Participant must have centrally-confirmed positivity for germline or somatic HRd status and tumor PD-L1 expression (TPS ≥ 1%). * Participant with NSCLC must have measurable disease by computed tomography (CT) scan as defined by RECIST v1.1: at least 1 tumor lesion ≥10 mm in the longest diameter, or a lymph node ≥15 mm in short axis measurement. * Participant with MPM must have Evaluable disease or measurable disease as assessed according to the mRECIST v1.1 * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 * Participant must be ≥ 18 years of age…